Cargando…
ABX464 (obefazimod) for patients with COVID-19 at risk for severe disease: miR-AGE, a randomized, double-blind placebo-controlled trial
BACKGROUND: ABX464 (obefazimod) is a small molecule that upregulates a single microRNA (miR-124) in immune cells and reduces the production of various inflammatory cytokines and chemokines. OBJECTIVE: We assessed the efficacy and safety of the standard of care (SoC) plus oral obefazimod (SoC plus AB...
| Autores principales: | , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10509999/ https://www.ncbi.nlm.nih.gov/pubmed/37781656 http://dx.doi.org/10.1016/j.jacig.2023.100140 |